Genzyme General, a division of Genzyme Corporation, is developing Fabrazyme (agalsidase beta), an enzyme replacement therapy
for patients with Fabry disease.
Sollpura represents the next generation of enzyme replacement therapy
for patients with EPI.
Xena, a pupil at Gilbertstone Primary School, in South Yardley, started the enzyme replacement therapy
on February 1 under the watchful eye of her parents Kat and Fazalriaz.
Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy
Lilly said the deal gives it a "promising entry into enzyme replacement therapy
," an area the drugmaker does not currently cover.
The CUPID trial (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MYDICAR, a genetically targeted enzyme replacement therapy
for advanced heart failure.
Creon/Kreon is the global market leader in pancreatic enzyme replacement therapy
for pancreatic exocrine insufficiency due to cystic fibrosis, chronic pancreatitis, and pancreatectomy and other conditions.
Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy
(PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI).
Manufacturing support from the NHLBI SMARTT program will enable production of additional material that will be used to determine the safety and efficacy of rhLCAT enzyme replacement therapy
for patients with familial LCAT deficiency - a potentially life-threatening illness for which there is no FDA-approved treatment.
a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy
High Affinity ZC-701 Fusion Enzyme Replacement Therapy
Demonstrates Superior Potency and Efficacy to Myozyme in Nonclinical Studies
Alnara's Pancreatic Enzyme Replacement Therapy
, Liprotamase, Currently Under FDA Review